Selecta Biosciences to Participate in LifeSci Partners Genetic Medicines Summit 2021
Selecta Biosciences, Inc. (NASDAQ: SELB) is a clinical-stage biotechnology company that uses its clinically validated ImmTOR platform to produce tolerogenic treatments to selectively reduce unwanted immune responses.
Stockholders will likely defer the CEO compensation increase for Selecta Biosciences, Inc. (NASDAQ: SELB) for now.
Has had an impressive share price performance. We believe that shareholders may, at the moment, be reluctant to increase the CEO’s salary. The data shows that the CEO compensation is less than the average total CEO compensation of $2.3 million, $550 million, if he were well paid, Selecta Biosciences, Inc. shareholders would generally be disappointed.
Announces the addition to its Board of Directors of Nishan de Silva, M.D. As Selecta continues to progress its clinical pipeline, Dr. de Silva will provide strategic leadership and operational experience. He is currently CEO and Director of AFYX Therapeutics, a company that focuses on the unmet needs of mucosal diseases.
Selecta Biosciences, Inc. (SELB) Stock Increases
Shares in Selecta Biosciences, Inc. (SELB) soared when the company announced positive data from its Phase 1 clinical trial of SelectaDNA in the treatment of ovarian cancer. SelectaDNA is a new therapeutic technology that selectively binds to cells in the human body that have cancerous or precancerous DNA, while leaving healthy cells unaffected. The Phase 1 clinical trial was designed to assess the safety and tolerability of SelectaDNA when administered intravenously as an intraoperative adjunct to surgical removal of ovarian cancer. The study met all of its primary endpoints, including safety.
Increase in Selecta Biosciences, Inc. (SELB) shares
Selecta Biosciences CEO Justin Gover states: “The final patient was enrolled in our Phase 1a/b ovarian cancer study and we are thrilled to report that the primary outcomes have been achieved. We now have on hand evidence of clinical data from a preclinical blood-based platform for SelectaDNA that gives us the confidence to proceed with a pivotal Phase 1 clinical trial in this indication. SelectaDNA in Preclinical Development Gover also notes that the results were promising for the company’s Preclinical SelectaDNA platform.
Positive data from the SelectaDNA Phase 1 trial in the treatment of ovarian cancer
“These very encouraging results for an experimental nanoparticle-based therapy suggest that SelectaDNA could potentially be used in combination with other cancer treatments to improve outcomes for ovarian cancer patients,” said Alan Carr, President and CEO of Selecta Biosciences , Inc. “The Phase 2 randomized trial, which will begin shortly, will investigate the use of SelectaDNA in combination with Merck Keytruda® anti-PD-1 therapy (pembrolizumab) for treatment of ovarian cancer in the first-line setting. ” Study participants received SelectaDNA in combination with Merck’s Keytruda anti-PD-1 therapy or saline control. Patients who received SelectaDNA in combination with Keytruda experienced a 100 percent complete response rate as determined by the scan.
SelectaDNA is a new therapeutic technology that selectively binds to cells in the human body that have cancerous or precancerous DNA, while leaving healthy cells unaffected.
It is derived from the company’s proprietary ProteinTamer® DNA binding domain. SelectaDNA binds to molecular receptors on human cancer cells that express fusions to the receptors that are targeted by SelectaDNA’s existing antimycotic chemotherapeutic agents. According to the company, SelectaDNA has already been used to treat two preclinical programs, one for mucositis in head and neck cancer and another for gastrointestinal stromal tumor (GIST), which show promise for first-line non-surgical treatment. In addition, DNA Selecta has been used in allogeneic T cell-based therapies that target human epidermal growth factor (HER) receptor 4 and 13, breast cancer cells expressing BRCA1 or BRCA2, and breast cancer cells. ovaries that express GHR.
The test met all your primary endpoints
The study involved 100 patients with stage I-III ovarian cancer and proven ovarian germline mutations who underwent hysterectomy. The main objective of the patients was a confirmed expression of SelectaDNA in the target tumor. Of the 100 patients, 66 patients showed confirmed SelectaDNA expression after surgical removal of their ovarian tumors. The mean lesion size was 2.5 cm, with the mean lesion size 2.6 cm. However, 63 patients did not have positive SelectaDNA expression. These data were confirmed by an independent third party and the resequencing of the remaining ovarian tumors. Median overall survival (OS) data were 6.9 months, including 4.1 months in patients who showed positive SelectaDNA expression.
In preclinical studies conducted by Selecta, the company claimed that SelectaDNA was successfully harvested, purified and expressed in the patient’s own cells and has no known interactions with the normal cell culture system. Given the positive data, the company moved forward with Phase 2 clinical trials in ovarian and testicular cancer indications in both the US and the EU. Preclinical results for Selecta in ovarian cancer were excellent. In preclinical studies, SelectaDNA performed as well or better than chemotherapy.